Will Doliprane still be available in France after its sale to an American fund? ? At what price? ?

Sanofi Opella's subsidiary, which produces and markets Doliprane in France, is set to be sold to an American fund. What consequences could this sale have on consumers? ?

The French consume 8,000 tonnes of paracetamol each year and it is the little yellow box that is most often found in their first aid kits. Used for headaches, aches and pains, fever, etc., Doliprane is even covered by Social Security when prescribed by a doctor on a prescription. Despite This success, the Sanofi Board of Directors decided on Thursday, October 10, to sell its subsidiary Opella, which produces and markets these drugs in France, to the American fund CD&R. This sale will allow Sanofi's new partner across the Atlantic to control 50% of the Opella subsidiary.

This announcement made the political class jump, who quickly assured that this represented a danger for health sovereignty. From La France Insoumise to the National Rally, including certain members of the presidential camp, this sale is strongly criticized. On his X account, Eric Coquerel (president of the Finance Committee and LFI deputy) believes that “it is unthinkable to abandon our sovereignty over the production of this type of medicine”. For his part, Jordan Bardella (president of the RN and MEP) believes that “the risks to our health sovereignty and to employment are considerable”: it would be incomprehensible for the state to let do".